18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) (ARGOS)

STUDY OVERVIEW

This study sponsored by Allergan aims to gather data on the safety and effectiveness of a bimatoprost intracameral implant in individuals diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT).

STUDY GOALS

This study evaluates the safety and efficacy of a bimatoprost intracameral implant in individuals diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT).

LOCATION

El Paso, Texas: El Paso Eye Surgeons P.A.

INCLUSION CRITERIA

  • Patients diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT) scheduled for bimatoprost intracameral implantation in at least one eye.

exclusion criteria

  • History of specific ocular surgeries in the eye scheduled for bimatoprost intracameral implant, including various glaucoma shunts, trabeculectomy, vitrectomy, or certain implants.

  • Concurrent or anticipated participation in another clinical trial involving investigational products or medical devices, or prior participation in another study involving Allergan bimatoprost intracameral implant.

The study population will include US patients with OAG or OHT who are scheduled for administration of a bimatoprost intracameral implant by their ophthalmologist.

For more information, visit ClinicalTrials.gov.